Sirtex: Result 2014

Sirtex had another bumper year of profit growth, with more to come as England expands patient access.

Just like most other companies, Sirtex Medical faces a daily struggle with competition, fighting to take its business away, but Sirtex's major competitor isn’t another business – it’s death. Liver cancer is the fifth most common cancer in the world and sadly has a five-year survival rate of just 15%.

The company’s main product is an internal radiotherapy for liver cancer known as SIR-Spheres. However, it’s currently only used as a last resort due to severe side effects – which means many patients die before they have the opportunity to use it.

{{content.question}}

{{ twilioFailed ? 'SMS Code Failed to Send…' : 'SMS Code Sent…' }}

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa
Mastercard

The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device


Register as a new member

(using a different email)

Related Articles